BR0107596A - Dispositivo osmótico contendo pseudoefedrina e um antagonista h1 - Google Patents

Dispositivo osmótico contendo pseudoefedrina e um antagonista h1

Info

Publication number
BR0107596A
BR0107596A BR0107596-9A BR0107596A BR0107596A BR 0107596 A BR0107596 A BR 0107596A BR 0107596 A BR0107596 A BR 0107596A BR 0107596 A BR0107596 A BR 0107596A
Authority
BR
Brazil
Prior art keywords
antagonist
osmotic
coated
device containing
osmotic device
Prior art date
Application number
BR0107596-9A
Other languages
English (en)
Inventor
Joaquina Faour
Marcelo A Ricci
Original Assignee
Osmotica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Corp filed Critical Osmotica Corp
Publication of BR0107596A publication Critical patent/BR0107596A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DISPOSITIVO OSMóTICO CONTENDO PSEUDOEFEDRINA E UM ANTAGONISTA H1". A presente invenção fornece um dispositivo osmótico contendo pseudoefedrina de liberação controlada no núcleo em combinação com um antagonista H1 de liberação rápida em um revestimento externo. Uma ampla faixa de antihistaminas antagonistas H1, especialmente fexofenadina, pode ser usada neste dispositivo. As modalidades em particular da invenção fornecem dispositivos osmóticos que têm perfis de liberação predeterminados. Uma modalidade do dispositivo osmótico inclui uma camada de revestimento externo que foi revestida por spray em vez de revestida por compressão sobre o dispositivo. O dispositivo com núcleo externo revestido por spray é menor e mais fácil de se engolir do que o dispositivo similar que tem um revestimento externo revestido por compressão. O dispositivo é útil para o tratamento de desordens relacionadas à congestão respiratória e de desordens relacionadas à alergia. Os presentes dispositivos fornecem PS e um antagonista H1 de acordo com perfis de liberação específicos em combinação com formulações específicas.
BR0107596-9A 2000-01-13 2001-01-08 Dispositivo osmótico contendo pseudoefedrina e um antagonista h1 BR0107596A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17587800P 2000-01-13 2000-01-13
US09/725,655 US6613357B2 (en) 2000-01-13 2000-11-29 Osmotic device containing pseudoephedrine and an H1 antagonist
PCT/US2001/000528 WO2001051038A1 (en) 2000-01-13 2001-01-08 Osmotic device containing pseudoephedrine and an h1 antagonist

Publications (1)

Publication Number Publication Date
BR0107596A true BR0107596A (pt) 2002-11-19

Family

ID=26871655

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107596-9A BR0107596A (pt) 2000-01-13 2001-01-08 Dispositivo osmótico contendo pseudoefedrina e um antagonista h1

Country Status (12)

Country Link
US (1) US6613357B2 (pt)
EP (1) EP1246612B1 (pt)
AR (1) AR026818A1 (pt)
AT (1) ATE397917T1 (pt)
AU (1) AU2001226349A1 (pt)
BR (1) BR0107596A (pt)
CA (1) CA2396145C (pt)
DE (1) DE60134387D1 (pt)
ES (1) ES2307584T3 (pt)
MX (1) MXPA02006867A (pt)
UY (1) UY26525A1 (pt)
WO (1) WO2001051038A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2307887A1 (en) * 1997-10-31 1999-05-14 Monsanto Company Gellan gum tablet coating
PE20020324A1 (es) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
ES2265022T3 (es) * 2001-03-14 2007-02-01 Pfizer Products Inc. Comprimido farmaceutico y procedimiento para su fabricacion.
WO2004019917A1 (es) * 2002-08-29 2004-03-11 Osmotica Corp. Dispositivo de liberacion de droga que contiene oseltamivir y un antagonista h1
JP2010180238A (ja) * 2001-11-22 2010-08-19 Daiichi Sankyo Healthcare Co Ltd 鼻炎用組成物
JP4549618B2 (ja) * 2001-11-22 2010-09-22 第一三共ヘルスケア株式会社 鼻炎用組成物
EP1350512A1 (en) * 2002-04-03 2003-10-08 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004014353A1 (en) * 2002-08-02 2004-02-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine
WO2004087095A2 (es) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositivo osmótico que contiene zafirlukast y un antagonista h1
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
CA2540308C (en) 2003-09-26 2013-08-06 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050208108A1 (en) * 2004-03-19 2005-09-22 Jannusch Leonard C Thermoplastic films and methods for making
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
EP2046303A1 (en) * 2006-06-30 2009-04-15 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
US20080095843A1 (en) * 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
US20080085311A1 (en) * 2006-10-05 2008-04-10 Tripathi Sanjay S Antihistamine-decongestant combinations
US20100143471A1 (en) * 2007-03-21 2010-06-10 Lupin Limited Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8450349B2 (en) 2007-09-13 2013-05-28 E5 Pharma LLC Long acting dual release product containing carbinoxamine and pseudoephedrine
AU2009308885A1 (en) * 2008-10-31 2010-05-06 Mcneil-Ppc, Inc. Osmotic tablet with a compressed outer coating
US8246988B2 (en) * 2009-01-05 2012-08-21 Mcneil-Ppc, Inc. Three layer tablet containing cetirizine, pseudoephedrine, and naproxen
US8252330B2 (en) * 2009-01-05 2012-08-28 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
CA2748728C (en) * 2009-01-05 2017-01-03 Mcneil-Ppc, Inc. Tablet containing cetirizine, pseudoephedrine, and naproxen containing a barrier layer
US20120100221A1 (en) 2009-06-02 2012-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
AU2010300641B2 (en) * 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
CN103554985B (zh) * 2013-10-18 2015-11-18 苏州大学 一种可反复开闭的双开关响应控制的分子释放系统、制备方法及应用
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
CN109589491B (zh) * 2019-01-29 2024-01-09 上海安翰医疗技术有限公司 自动给药装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
ATE118345T1 (de) * 1990-08-07 1995-03-15 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
CA2261787C (en) * 1997-05-30 2006-11-14 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
IN186245B (pt) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
IN188720B (pt) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine

Also Published As

Publication number Publication date
MXPA02006867A (es) 2004-04-02
DE60134387D1 (de) 2008-07-24
US6613357B2 (en) 2003-09-02
ES2307584T3 (es) 2008-12-01
CA2396145A1 (en) 2001-07-19
EP1246612B1 (en) 2008-06-11
ATE397917T1 (de) 2008-07-15
AU2001226349A1 (en) 2001-07-24
US20020102305A1 (en) 2002-08-01
CA2396145C (en) 2008-07-22
WO2001051038A1 (en) 2001-07-19
EP1246612A1 (en) 2002-10-09
UY26525A1 (es) 2001-09-28
EP1246612A4 (en) 2006-04-05
AR026818A1 (es) 2003-02-26

Similar Documents

Publication Publication Date Title
BR0107596A (pt) Dispositivo osmótico contendo pseudoefedrina e um antagonista h1
AR034787A1 (es) Dispositivo de liberacion de droga que contiene oseltamivir y un antagonista h1
CA2396156A1 (en) Osmotic device containing venlafaxine and an anti-psychotic agent
HUP0401714A2 (hu) Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái
UY26534A1 (es) Dispositivo osmótico que contiene alprazolam y un agente antipsicótico
HUP0401191A2 (hu) Opioid agonistát, valamint leadható és álcázott antagonistát tartalmazó készítmények
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
AP1748A (en) Chronotherapeutic dosage forms.
BR0002607A (pt) Composições lìquidas rapidamente absorvidas
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
BRPI0212116B8 (pt) sistemas de distribuição tópica de emulsão multivesicular e processo para sua preparação
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
BRPI0213653B8 (pt) formulação farmacêutica que contém o 3-(3-dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo
AR023228A1 (es) Composiciones en espuma estables
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
CL2004000564A1 (es) Formulacion farmaceutica para administracion oral que comprende uno o mas agentes farmaceuticamente activos y cacao en polvo.
BR9807368A (pt) Comprimidos de oxacarvazepina revestidos com pelìcula
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
WO2004056335A3 (es) Dispositivo de liberación que contiene venlafaxina y memantina
BR0114272A (pt) Formulação farmacêutica de liberação prolongada independente da força iÈnica
BRPI0619868A8 (pt) Dispersão sólida compreendendo um ingrediente ativo tendo um ponto de fusão baixo e comprimido para administração oral compreendendo o mesmo
BR0313773A (pt) Formas farmacêuticas de dosagem sólida exibindo perfil de liberação de fármaco reprodutìvel
BR0015225A (pt) Tratamento de enfisema utilizando antagonistas retinóides seletivos para rar
BR0314777A (pt) Formas de dosagem de liberação modificada

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/22, A61K 9/24, A61K 9/44

Ipc: A61K 9/24 (2010.01), A61K 31/137 (2010.01), A61K 9

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: OSMOTICA KERESKEDELMI ES SZOLGALGATO KFT (HU)

Free format text: TRANSFERIDO DE: OSMOTICA CORP.

B25G Requested change of headquarter approved

Owner name: OSMOTICA KERESKEDELMI ES SZOLGALGATO KFT (HU)